Global Journal of Research in
Biology and Pharmacy
Journal homepage: https://gsjournals.com/gjrbp/
ISSN: 2980-4221 (Online)

(REVIEW ARTICLE)

Check for updates

EMERGING STRATEGIES AGAINST ANTIMICROBIAL RESISTANCE: PHAGE THERAPY, ANTIMICROBIAL PEPTIDES, AND ANTIBIOTIC ADJUVANTS

T. Mayank Reddy *

Sri Venkateswara College of Pharmacy, RVS Nagar, Andhra Pradesh, India.
* Corresponding Author

Global Journal of Research in Biology and Pharmacy, 2024, 03(04), 001–005

Publication history: Received on 12 August 2024; revised on 21 October 2024; accepted on 26 October 2024

Article DOI: https://doi.org/10.58175/gjrbp.2024.3.4.0187

ABSTRACT

Antimicrobial resistance is a global health crisis that threatens the efficacy of existing antibiotics and undermines modern medicine. The pipeline of new conventional antibiotics is insufficient to meet the growing burden of resistant infections, prompting urgent interest in alternative and adjunctive strategies. This review critically examines three emerging approaches: bacteriophage therapy, antimicrobial peptides, and antibiotic adjuvants. Phage therapy exploits naturally occurring viruses that specifically infect and lyse bacteria, offering high specificity and the ability to co-evolve with resistant pathogens. Clinical evidence from compassionate use, case series, and early trials suggests efficacy in difficult-to-treat infections, but standardized manufacturing, regulatory frameworks, and pharmacokinetics remain challenging. Antimicrobial peptides are host-defense-inspired molecules with broad-spectrum activity and lower propensity for resistance, yet their clinical translation has been limited by stability, toxicity, and cost. Antibiotic adjuvants aim to restore the activity of existing antibiotics by inhibiting resistance mechanisms such as β-lactamases, efflux pumps, or biofilm formation, with several β-lactamase inhibitor combinations already in clinical use. The review compares these strategies, highlights their limitations, and discusses combination approaches that may enhance efficacy while minimizing resistance development. Future directions include engineered phages, peptide mimetics, and novel adjuvants targeting emerging resistance determinants. A coordinated, multidisciplinary effort will be essential to translate these innovations into clinical practice.

Keywords: Antimicrobial Resistance; Phage Therapy; Antimicrobial Peptides; Antibiotic Adjuvants; B-Lactamase Inhibitors; Biofilm

1 INTRODUCTION

Antimicrobial resistance is one of the most pressing threats to global public health. The World Health Organization has declared antimicrobial resistance a top ten global health threat, with an estimated 1.27 million deaths directly attributable to drug-resistant bacterial infections in 2019. The rise of multidrug-resistant and extensively drug-resistant organisms, including methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacterales, and multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, has led to infections that are increasingly difficult or impossible to treat with available antibiotics. Despite the urgent need, the development of new antibiotics

has slowed dramatically due to scientific challenges, high costs, and low financial returns. Many large pharmaceutical companies have exited the antibiotic space, leaving a fragile pipeline heavily reliant on small biotech firms.

In this context, alternative and adjunctive strategies have gained significant attention. Bacteriophage therapy, which uses viruses that infect and kill specific bacteria, was first explored in the early twentieth century but was largely abandoned in the West after the discovery of antibiotics. The global antimicrobial resistance crisis has renewed interest in phage therapy, particularly for compassionate use in patients with recalcitrant infections. Antimicrobial peptides, which are components of the innate immune system across many organisms, offer broad-spectrum activity and a lower propensity for resistance, but their clinical development has been hampered by stability and toxicity issues. Antibiotic adjuvants do not possess intrinsic antibacterial activity but rather enhance the effectiveness of existing antibiotics by inhibiting resistance mechanisms. The most successful adjuvants are β-lactamase inhibitors, which have become standard of care for certain resistant infections.

This review critically evaluates the current state of these three emerging strategies, focusing on mechanisms of action, clinical evidence through mid-2024, and key challenges. It also discusses the potential for combination approaches and future research directions.

2 BACTERIOPHAGE THERAPY

2.1 Mechanisms and Advantages

Bacteriophages, or phages, are viruses that infect and replicate within bacterial cells, ultimately causing lysis and death. They are highly specific, often targeting a single bacterial strain or species, which minimizes collateral damage to the host microbiota. Phages can also penetrate biofilms and replicate at the site of infection, achieving high local concentrations. Importantly, phages can co-evolve with bacteria, potentially overcoming resistance through natural selection. They are abundant in nature and can be isolated rapidly, enabling personalized therapy for refractory infections.

2.2 Clinical Evidence

Clinical experience with phage therapy has largely consisted of compassionate use and case series, with a growing number of controlled trials. A systematic review of compassionate use cases found high rates of clinical improvement, but publication bias and lack of controls limit interpretation. Early randomized trials have evaluated phage therapy for chronic otitis, diabetic foot ulcers, urinary tract infections, and burn wound infections, with mixed results. For example, a randomized trial of a phage cocktail for chronic Pseudomonas aeruginosa otitis showed significant reduction in bacterial load compared with placebo. A trial of phage therapy for Escherichia coli urinary tract infection demonstrated safety but did not meet its primary efficacy endpoint, possibly due to phage inactivation by urine. In critically ill patients with multidrug-resistant infections, phage therapy has been used successfully in combination with antibiotics, with several case series reporting clearance and survival. However, robust phase 3 data are lacking, and the field faces significant regulatory and manufacturing hurdles.

2.3 Challenges

Phage therapy presents unique challenges:

- Narrow host range: Requires phage susceptibility testing and often personalized phage selection.
- Pharmacokinetics: Phages are large biologics that may be cleared rapidly by the immune system, and optimal dosing and delivery are not well defined.
- Resistance development: Bacteria can develop resistance to phages through receptor mutation, CRISPR-Cas systems, or restriction-modification. Phage cocktails or sequential therapy can mitigate this.
- Regulatory framework: Phages are biological products, and current regulatory pathways are not well suited to personalized mixtures that may change over time.
- Manufacturing: Purification, stability, and quality control are more complex than for small molecules.

Despite these challenges, phage therapy is advancing, with several biotechnology companies developing standardized phage products and seeking regulatory approval.

3 ANTIMICROBIAL PEPTIDES

3.1 Mechanisms and Advantages

Antimicrobial peptides are short, cationic, amphipathic peptides that are components of the innate immune system in bacteria, plants, insects, and mammals. They kill bacteria primarily by disrupting membrane integrity, although some have intracellular targets. Their broad-spectrum activity, rapid killing, and ability to neutralize endotoxins are attractive properties. Because their primary target is the bacterial membrane, resistance development is less common than for conventional antibiotics, though some resistance mechanisms exist (e.g., membrane modification, efflux).

3.2 Clinical Progress

Despite extensive preclinical research, only a limited number of antimicrobial peptides have reached clinical trials, and few have achieved regulatory approval. Polymyxins (colistin, polymyxin B) are cyclic lipopeptide antibiotics with membrane-disrupting activity and are considered last-resort agents for multidrug-resistant Gram-negative infections, although their nephrotoxicity and neurotoxicity limit use. Daptomycin is a lipopeptide antibiotic used for Gram-positive infections, particularly MRSA and vancomycin-resistant enterococci. Gramicidin is used topically. Novel antimicrobial peptides, such as pexiganan (a magainin analog) and omiganan, have been evaluated for diabetic foot ulcers and catheter-related infections but have not gained widespread approval due to efficacy or safety concerns. More recently, engineered peptides and peptidomimetics are in development, aiming to improve stability and reduce toxicity. For example, murepavadin, a peptide targeting Pseudomonas aeruginosa outer membrane protein LptD, showed promise in early trials but was associated with renal toxicity.

3.3 Challenges

Clinical translation of antimicrobial peptides has been hindered by:

- Proteolytic instability: Peptides are rapidly degraded in serum and by tissue proteases.
- Systemic toxicity: Many peptides are hemolytic or nephrotoxic at therapeutic concentrations.
- Cost of synthesis: Large-scale synthesis is expensive, and yields are often low.
- Limited oral bioavailability: Most peptides require parenteral administration.

Efforts to overcome these challenges include incorporation of D-amino acids, cyclization, PEGylation, and development of small-molecule peptidomimetics that retain the mechanism but improve drug-like properties.

4 ANTIBIOTIC ADJUVANTS

4.1 β-Lactamase Inhibitors

β-Lactam antibiotics are the most widely used class, but their efficacy is compromised by β-lactamase enzymes that hydrolyze the β-lactam ring. β-Lactamase inhibitors are compounds that inactivate these enzymes, restoring the activity of the partner β-lactam. Clavulanic acid, sulbactam, and tazobactam are first-generation inhibitors with activity against many class A β-lactamases. Newer inhibitors, such as avibactam, vaborbactam, relebactam, and enmetazobactam, have broader activity, including against some class C and class D β-lactamases. Combinations such as ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefepime-enmetazobactam have become important options for carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa. Clinical trials have demonstrated efficacy in complicated urinary tract infections, intra-abdominal infections, and hospital-acquired pneumonia. However, resistance to these combinations is emerging, including mutations in β-lactamases and porin loss.

4.2 Efflux Pump Inhibitors

Efflux pumps are bacterial membrane proteins that export antibiotics, contributing to multidrug resistance. Inhibitors of efflux pumps, such as phenylalanine-arginine β-naphthylamide, have shown in vitro ability to potentiate antibiotics against Gram-negative bacteria, but none have entered clinical use due to toxicity and poor pharmacokinetics. Newer efflux pump inhibitors are under investigation, but this remains a challenging area.

4.3 Biofilm Disruptors and Quorum Sensing Inhibitors

Biofilms are structured bacterial communities embedded in a matrix that protects cells from antibiotics and host defenses. Agents that disrupt biofilms or inhibit quorum sensing can enhance antibiotic penetration and reduce virulence. Several compounds, including enzymes that degrade the matrix (e.g., DNase, alginate lyase) and quorum sensing inhibitors (e.g., azithromycin at sub-inhibitory concentrations), have shown promise in vitro and in animal models, but clinical evidence is limited.

4.4 Other Adjuvants

Adjuvants that enhance host immunity, such as antimicrobial peptides used as adjuvants, or that target bacterial virulence factors, are being explored. For example, monoclonal antibodies against toxins (e.g., obiltoxaximab for anthrax) and anti-virulence compounds are in development.

5 COMPARISON AND COMBINATION STRATEGIES

Phage therapy, antimicrobial peptides, and antibiotic adjuvants each have distinct strengths and limitations. Phages are highly specific and can replicate at the site of infection, but their narrow host range and regulatory complexity limit widespread use. Antimicrobial peptides have broad-spectrum activity and lower resistance propensity, but stability and toxicity are significant barriers. Adjuvants are attractive because they restore the activity of existing, well-characterized antibiotics, and several have already achieved regulatory approval. However, adjuvants do not address pathogens that are intrinsically resistant or those with multiple resistance mechanisms.

Combination approaches may offer synergistic benefits. Phages combined with antibiotics can enhance bacterial killing and reduce resistance emergence. Antimicrobial peptides used as adjuvants can permeabilize membranes and increase antibiotic uptake. Adjuvants targeting biofilms can improve antibiotic penetration. The challenge is to design rational combinations based on mechanisms and to evaluate them in well-designed clinical trials.

6 FUTURE PERSPECTIVES

Emerging strategies will need to overcome scientific, regulatory, and economic hurdles. Key directions include:

- Phage engineering: Synthetic biology can create phages with expanded host range, enhanced biofilm penetration, or delivery of antimicrobial genes.
- Peptide mimetics and stabilized peptides: Non-peptide scaffolds that mimic antimicrobial peptide activity may improve drug-likeness.
- Novel adjuvants targeting emerging resistance: As new resistance mechanisms emerge (e.g., metallo-β-lactamases, OXA carbapenemases), new inhibitors will be needed.
- Host-directed therapies: Boosting innate immunity or modulating inflammation may complement direct antimicrobial strategies.
- Regulatory innovation: Adaptive pathways, real-world evidence, and streamlined approval for personalized phage therapy may accelerate access.
- Economic incentives: Addressing the market failure in antimicrobial development will require push and pull incentives, including subscription models and public–private partnerships.

7 CONCLUSION

Antimicrobial resistance demands urgent innovation. Phage therapy, antimicrobial peptides, and antibiotic adjuvants represent promising but distinct approaches that are at different stages of clinical development. Phage therapy offers precision and self-amplification but faces regulatory and manufacturing challenges. Antimicrobial peptides have broad potential but require solutions to stability and toxicity. Antibiotic adjuvants, particularly β-lactamase inhibitors, have already achieved clinical success and will continue to evolve. A combined approach, integrating these strategies with prudent antibiotic use and infection prevention, will be essential to preserve the effectiveness of antimicrobial therapy.

REFERENCES

[1] Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.

[2] World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report. 2022.

[3] Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.

[4] Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954-17.

[5] Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35–45.

[6] Leitner L, Ujmajuridze A, Chanishvili N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427–436.

[7] Wright A, Hawkins CH, Anggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa. Clin Otolaryngol. 2009;34(4):349–357.

[8] Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8(6):769–783.

[9] Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389–395.

[10] Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov. 2012;11(1):37–51.

[11] Vaara M. Polymyxins and their potential next generation as therapeutic antibiotics. Front Microbiol. 2019;10:1689.

[12] Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.

[13] Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247.

[14] van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–241.

[15] Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187–212.

[16] Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2001;45(1):105–116.

[17] Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9(1):522–554.

[18] Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Mol Cell. 2015;58(4):586–597.

[19] Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–733.

[20] Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239–251.